Kim Hye-Won, Seo Dong-Man, Shin Hong Ju, Park Jeong-Jun, Yoon Tae-Jin
Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Korea.
Korean J Thorac Cardiovasc Surg. 2011 Apr;44(2):108-14. doi: 10.5090/kjtcs.2011.44.2.108. Epub 2011 Apr 14.
Homograft cardiac valves and valved-conduits have been available in our institute since 1992. We sought to determine the long-term outcome after right ventricular outflow tract (RVOT) reconstruction using homografts, and risk factors for reoperation were analyzed.
We retrospectively reviewed 112 patients who had undergone repair using 116 homografts between 1992 and 2008. Median age and body weight at operation were 31.2 months and 12.2 kg, respectively. The diagnoses were pulmonary atresia or stenosis with ventricular septal defect (n=93), congenital aortic valve diseases (n=15), and truncus arteriosus (N=8). Mean follow-up duration was 79.2±14.8 months.
There were 10 early and 4 late deaths. Overall survival rate was 89.6%, 88.7%, 86.1% at postoperative 1 year, 5 years and 10 years, respectively. Body weight at operation, cardiopulmonary bypass (CPB) time and aortic cross-clamping (ACC) time were identified as risk factors for death. Forty-three reoperations were performed in thirty-nine patients. Freedom from reoperation was 97.0%, 77.8%, 35.0% at postoperative 1 year, 5 years and 10 years respectively. Small-sized graft was identified as a risk factor for reoperation.
Although long-term survival after RVOT reconstruction with homografts was excellent, freedom from reoperation was unsatisfactory, especially in patients who had small grafts upon initial repair. Thus, alternative surgical strategies not using small grafts may need to be considered in this subset.
自1992年起,我院就已开始使用同种异体心脏瓣膜和带瓣管道。我们试图确定使用同种异体移植物进行右心室流出道(RVOT)重建后的长期结果,并分析再次手术的危险因素。
我们回顾性分析了1992年至2008年间接受116次同种异体移植物修复的112例患者。手术时的中位年龄和体重分别为31.2个月和12.2千克。诊断包括肺动脉闭锁或狭窄合并室间隔缺损(n = 93)、先天性主动脉瓣疾病(n = 15)和动脉干(n = 8)。平均随访时间为79.2±14.8个月。
有10例早期死亡和4例晚期死亡。术后1年、5年和10年的总生存率分别为89.6%、88.7%和86.1%。手术时体重、体外循环(CPB)时间和主动脉阻断(ACC)时间被确定为死亡的危险因素。39例患者进行了43次再次手术。术后1年、5年和10年再次手术的无复发生存率分别为97.0%、77.8%和35.0%。小尺寸移植物被确定为再次手术的危险因素。
尽管使用同种异体移植物进行RVOT重建后的长期生存率很高,但再次手术的无复发生存率并不理想,尤其是初次修复时使用小移植物的患者。因此,对于这部分患者可能需要考虑不使用小移植物的替代手术策略。